July 22, 2020

BlueSphere Bio Appoints Drug Development Leader Dr. Michael Geffner as Chief Medical Officer

BlueSphere Bio has appointed a veteran drug development leader, Michael Geffner, M.D., M.B.A., as the company’s first chief medical officer.

July 9, 2020

BlueSphere Bio Names Immune Oncology Pioneers to Scientific Advisory Board

Members of the scientific advisory board include Carl June, M.D., Ulrich von Andrian, M.D, Greg Delgoffe, Ph.D, and Marc Jenkins, Ph.D.

July 31, 2019

Immune Oncology Innovator BlueSphere Bio Names Veteran Biotech Leader David Apelian as CEO

With Pitt Expertise and UPMC Funding, BlueSphere’s TCXpress Platform to Develop Rapid, Personalized T-Cell Therapies for Cancer Treatment.